obesity

News

The alliance between Novo Nordisk and telehealth firm Hims & Hers for the distribution of GLP-1 agonist weight-loss therapies has ended in acrimony.

News

Novo Nordisk's phase 3 data for CagriSema at ADA raises questions about how weight loss data in obesity trials are interpreted.

News

Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.

News

US telehealth company Hims & Hers has reached a deal to buy its UK counterpart Zava as part of a broader push into Europe.

News

A study has suggested the benefits of GLP-1 agonists could extend to a reduction in the risk of a slew of cancers associated with being overweight.

News

A new licensing deal with Septerna suggests Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity.